ArticleTherapeutic advances in chronic disease2021
Steatosis grading consistency between controlled attenuation parameter and MRI-PDFF in monitoring metabolic associated fatty liver disease.
Article in Therapeutic advances in chronic disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Recent advances in the treatment of chronic liver diseases: focus on MASLD/MASH-related fibrosis.Clinical and experimental hepatology · 2026Review
- Thermoacoustic Ultrasound Assessment of Liver Steatosis-A Novel Approach for MASLD Diagnosis.Diagnostics (Basel, Switzerland) · 2026Article
- Diagnostic performance of controlled attenuation parameter for grading hepatic steatosis in MASLD: an MRI-PDFF-referenced study in a Chinese cohort.Frontiers in medicine · 2026Article
- Liver fibrosis with persistently normal alanine transaminase levels exhibits a distinct treatment response in MASLD.BMJ open gastroenterology · 2025Article
- Effects of sodium-glucose co-transporter-2 inhibitors on body composition and liver fat markers in non-alcoholic fatty liver disease: a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Association between the TyG index and MAFLD and its subtypes: a population-based cross-sectional study.BMC gastroenterology · 2025Article
- Application of Steatotic Donor Livers in Liver Transplantation.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2025Review
- Application and research progress of magnetic resonance proton density fat fraction in metabolic dysfunction-associated steatotic liver disease: a comprehensive review.Abdominal radiology (New York) · 2025Review
- Unrecognised rural-urban disparities in epidemiology of metabolic-associated fatty liver disease in the representative area of China.BMJ nutrition, prevention & health · 2025Article
- Correlation between Liver fat Content Determined by Ultrasonic Attenuation Imaging and Lipid Metabolism in Patients with Non-Alcoholic Fatty Liver DiseaseCurrent medical imaging · 2025Article
- Association Between Ultraprocessed Food Consumption and Metabolic Disorders in Children and Adolescents with Obesity.Nutrients · 2024Article
- Machine learning prediction of hepatic steatosis using body composition parameters: A UK Biobank Study.npj aging · 2024Article
- First-in-human diagnostic study of hepatic steatosis with computed ultrasound tomography in echo mode.Communications medicine · 2023Article
- Non-Invasive Diagnostic of NAFLD in Type 2 Diabetes Mellitus and Risk Stratification: Strengths and Limitations.Life (Basel, Switzerland) · 2023Review
- An Optimized Strategy Based on Conventional Ultrasound for Diagnosing Metabolic Dysfunction-Associated Steatotic Liver Disease.Diagnostics (Basel, Switzerland) · 2023Article
- Impact of skeletal muscle mass evaluating methods on severity of metabolic associated fatty liver disease in non-elderly adults.The British journal of nutrition · 2023Article
- Non-invasive evaluation of liver steatosis with imaging modalities: New techniques and applications.World journal of gastroenterology · 2023Review
- Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease Among Hospital Staff.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Article
- The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Ultrasound Methods for the Assessment of Liver Steatosis: A Critical Appraisal.Diagnostics (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe consistency in steatosis grading between magnetic resonance imaging-based proton density fat fraction (MRI-PDFF) and controlled attenuation parameter (CAP) before and after treatment remains unclear. This study aimed to compare the diagnostic accuracy of steatosis grading between MRI-PDFF and CAP using liver biopsy as standard and to evaluate the value of monitoring changes in steatosis grading with CAP during follow-up utilizing MRI-PDFF as a reference.
methodsConsecutive patients from a biopsy cohort and a randomized controlled trial were included in this study and classified into 3 groups (the biopsy, orlistat treatment, and routine treatment subgroups). Hepatic steatosis was measured
resultsA total of 209 consecutive patients were enrolled. MRI-PDFF and CAP showed comparable diagnostic accuracy for detecting pathological steatosis [⩾S1, area under the receiver operating characteristic curve (AUC) = 0.984 and 0.972, respectively]; in contrast, CAP presented significantly lower AUCs in grades S2-3 and S3 (0.820 and 0.815, respectively). The CAP values correlated well with the MRI-PDFF values at baseline and at the 6th month (
conclusionsCAP has decreased value for the initial screening of moderate-severe steatosis and is limited in monitoring changes in steatosis during treatment. The confirmation of steatosis grading with MRI-PDFF remains necessary.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.